0.97%
-0.71%
2.96%
17.96%
134.01%
-51.96%
-30.62%
Stock-Card

AI Spotlight on OXB

Company Description

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally.The company operates in two segments, Platform and Product.Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes.


The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication.The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre.The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development.


Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Market Data

Last Price 417
Change Percentage 0.97%
Open 413
Previous Close 413
Market Cap ( Millions) 442
Volume 157837
Year High 455
Year Low 167
M A 50 420.33
M A 200 367.95

Financial Ratios

FCF Yield -16.32%
Dividend Yield 0.00%
ROE -202.50%
Debt / Equity 166.48%
Net Debt / EBIDTA -61.41%
Price To Book 6.62
Price Earnings Ratio -3.09
Price To FCF -6.13
Price To sales 4.54
EV / EBITDA -10.0

News

Business Breakdown

Expected Mid-Term Growth

Segment n°1 -> Platform

Expected Growth : 11.43 %

What the company do ?

Oxford Biomedica's platform is a lentiviral vector-based gene therapy technology for the treatment of various diseases, including ocular and inherited diseases.

Why we expect these perspectives ?

Oxford Biomedica's platform growth is driven by increasing adoption of gene and cell therapies, strong partnerships with leading pharmaceutical companies, and a growing pipeline of novel therapies. The company's LentiVector platform has demonstrated success in multiple indications, and its scalable manufacturing capabilities position it for long-term growth.

Segment n°2 -> Product

Expected Growth : 11.3 %

What the company do ?

Oxford Biomedica plc's product is LentiVector, a gene-based therapy platform for cancer and inherited diseases, utilizing lentiviral vectors for gene delivery.

Why we expect these perspectives ?

Oxford Biomedica's 11.3% growth is driven by increasing demand for its lentiviral vector products, particularly in the gene therapy market. Strong partnerships with leading biotech companies, such as Novartis and Bristol-Myers Squibb, contribute to revenue growth. Additionally, the company's expanding manufacturing capacity and investment in research and development support its growth momentum.

Oxford Biomedica Plc Products

Product Range What is it ?
LentiVector LentiVector is a lentiviral vector technology used for gene therapy, allowing for the delivery of therapeutic genes to cells.
5T4 antibody 5T4 is a tumor-associated antigen used as a target for cancer therapies, including antibody-based treatments.
OXB-102 OXB-102 is a gene therapy for the treatment of Parkinson's disease, using a lentiviral vector to deliver a therapeutic gene to the brain.
OXB-201 OXB-201 is a gene therapy for the treatment of ocular diseases, including wet age-related macular degeneration.
Vector manufacturing Oxford Biomedica provides contract manufacturing services for lentiviral vectors, supporting the development of gene therapies.

Oxford Biomedica plc's Porter Forces

The threat of substitutes for Oxford Biomedica plc is moderate due to the presence of alternative gene therapy products and services in the market.

The bargaining power of customers for Oxford Biomedica plc is low due to the specialized nature of its gene therapy products and services, which limits the ability of customers to negotiate prices.

The bargaining power of suppliers for Oxford Biomedica plc is moderate due to the presence of multiple suppliers of raw materials and services, which limits their negotiating power.

The threat of new entrants for Oxford Biomedica plc is high due to the growing demand for gene therapy products and services, which attracts new companies to enter the market.

The intensity of rivalry for Oxford Biomedica plc is high due to the presence of established competitors in the gene therapy market, which leads to intense competition for market share.

Strength

Weaknesses

Opportunities

Threats

Capital Structure

Value
Debt Weight 36.31%
Debt Cost 8.63%
Equity Weight 63.69%
Equity Cost 8.63%
WACC 8.63%
Leverage 57.01%

Oxford Biomedica plc : Quality Control

Historical Valuation

Price/Earnings Ratio

Margin Valuation

Peers Valuation

Competitors

Company Rational
EVGN Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through …
AFMD Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has …
SLGL Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead …
MLEC Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and …
EXAI Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate …

Peers Metrics

DCF BETA

Parameters

Short Term Growth
Short term Time
Long-Term Growth
WACC
Target Price
4.17$
Current Price
4.17$
Potential
-0.00%

Expected Cash-Flows

Scoring Insights

Peers Group Analysis

🥇

Oxford Biomedica Logo
Oxford Biomedica
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

🥈

Moolec Science Logo
Moolec Science
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

🥉

Evogene Logo
Evogene
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

4

Sol-Gel Technologies Logo
Sol-Gel Technologies
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

5

Exscientia Logo
Exscientia
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

6

Affimed Logo
Affimed
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->